And perhaps those veggies provide nutrients that reduce cataract risk. Drops are placed in your eyes to widen, or dilate, the pupils. Age-related cataracts. Severe trauma to the eye, eye surgery, or intra ocular inflammation can also cause cataracts to develop more rapidly. And the rate of corneal higher-order aberrations was significantly higher in the LASIK group than in the control groups. Eyeball Illustration – Cataracts The lens is a portion of the eye that is normally clear. But as we age, some of the protein may clump together and start to cloud a small area of the lens. The first eye needs to heal. Can problems develop after surgery?
Cataract surgery patients, many of whom are older, may have difficulty instilling eyedrops and thus adhering to the current post-surgical standard of care, a topical corticosteroid eyedrop. We believe that iontophoretic EGP-437 administered by the surgeon has the potential to significantly reduce adherence burden and dramatically improve patient outcomes. We are excited by the data this trial has generated to-date and look forward to the continued evaluation of our lead iontophoretic product in this highly prevalent indication. About EyeGate EyeGate Pharma ( EYEG ) is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products therapeutics and drug delivery systems for treating diseases and disorders of the eye. EGP-437, the Companys first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGates proprietary innovative drug delivery system, the EyeGate II Delivery System. In addition, EyeGate is developing, through its wholly-owned Jade subsidiary, products using cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S), a modified form of the natural polymer hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties. http://www.edwardscohousing.org/gabriellahernandezjournal/2016/08/06/most-health-insurance-plans-also-require-you-to-pay-an-additional-co-pay-commonly-75-100-for-each-emergency-room-visit/The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. EyeGate intends to initiate a clinical study for Jades lead product candidate for corneal epithelial defects by the end of the year 2016. For more information, please visit www.EyeGatePharma.com . Read More Safe Harbor Statement Some of the statements in this press release are forward-looking and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. http://experteyedoc.holyfamilyschooljasper.com/2016/07/21/if-you-are-going-out-to-eat-and-suffer-from-sneezing-too-much-then-make-sure-you-carry-some-tissues-along-with-you/These forward-looking statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGates products, including EyeGates EGP-437 combination product, and those of Jade Therapeutics, Inc., a wholly owned subsidiary of EyeGate, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading Risk Factors contained in EyeGates Annual Report on Form 10-K filed with the SEC on March 30, 2016, EyeGates Quarterly Report on Form 10-Q filed with the SEC on May 13, 2016 or described in EyeGates other public filings.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/eyegate-announces-positive-top-line-123000277.html